Dossier assessment

Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A25-138
Last updated

Report documents

  1. Extract of dossier assessment

    Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 123 kB, DE, not accessible
  2. Dossier assessment

    Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 650 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A25-138

Drug assessment at a glance

  1. Drug assessment at a glance

    Avapritinib (gastrointestinal stromal tumours) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 201 kB, EN, not accessible

Dossier assessment

Indication:

Adult patients with unresectable or metastatic gastrointestinal stromal tumours (GIST) harbouring the platelet-derived growth factor receptor alpha (PDGFRA) D842V mutation

Result of dossier assessment:

Added benefit not proven

Project details

Project no.
A25-138
Commission
Commission awarded on 31.10.2025 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A25-138

Connected Projects

  1. Dossier assessment

    Avapritinib (indolent systemic mastocytosis) – Assessment according to §35a (para. 1, sentence 11) Social Code Book V

    Project no.
    G23-32
    Last updated

    Status: Commission completed

  2. Dossier assessment

    Avapritinib (advanced systemic mastocytosis) – Assessment according to §35a (para. 1., sentence 11)

    Project no.
    G22-10
    Last updated

    Status: Commission completed

  3. Dossier assessment

    Avapritinib (GIST) - Assessment according to §35a (para. 1., sentence 11) Social Code Book V

    Project no.
    G20-26
    Last updated

    Status: Commission completed

  4. Dossier assessment

    Avapritinib (advanced systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-137
    Last updated

    Status: Commission completed

  5. Dossier assessment

    Avapritinib (indolent systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A25-136
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form